Patients with hepatitis B major triple-positive who have normal liver biochemistry, no abnormal coagulation function and stable disease can receive the new crown vaccine, which generally has no effect. Patients can observe first after vaccination, and if there are uncomfortable reactions, such as dizziness, nausea, weakness, loss of appetite, etc., they can go to the hospital for liver biochemistry and other related tests in time to clarify whether they are caused by hepatitis B or common side effects of the vaccine. At present, the state stipulates that patients with hepatitis B virus carrier status and hepatitis who are in stable condition and without hepatitis activity can be vaccinated with the new crown vaccine normally, which means that patients with hepatitis B major triplet can be vaccinated with the new crown vaccine if their condition is stable. Patients with severe liver disease, including patients with acute and chronic liver failure, patients with decompensated cirrhosis with jaundice, ascites, and coagulation dysfunction, and patients with acute hepatitis, cannot receive the New Crown vaccine for the time being. The New Crown vaccine can be administered only when the disease is under stable control. Patients with hepatitis B major triple-positive disease do not need to stop taking antiviral medication during the antiviral period as it will not affect the effectiveness of the New Crown vaccination. Patients who need to discontinue their medication must have their doctor’s consent. Discontinuation of nucleoside antivirals may lead to aggravation of the patient’s condition and may even induce liver failure.